Haddadin Yezan Munther 4
4 · Outlook Therapeutics, Inc. · Filed Oct 5, 2020
Insider Transaction Report
Form 4
Haddadin Yezan Munther
Director
Transactions
- Award
Stock Option (Right to Buy)
2020-10-01+290,372→ 290,372 totalExercise: $0.71Exp: 2030-10-01→ Common Stock (290,372 underlying) - Award
Stock Option (Right to Buy)
2020-10-05$0.51/sh+160,474$82,500→ 160,474 totalExercise: $0.71Exp: 2030-10-05→ Common Stock (160,474 underlying)
Footnotes (2)
- [F1]The options were granted under the Issuer's 2015 Equity Incentive Plan (the "2015 Plan") and shall vest in full on October 1, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan, subject to the Reporting Person providing continuous service to the Issuer through such event.
- [F2]The options were granted under the 2015 Plan in lieu of $82,500 cash fees payable under the Issuers's non-employee Director compensation program and vest in four equal quarterly installments on the last day of each fiscal quarter such that they are vested in full on September 30, 2021, subject to the Reporting Person providing continuous service to the Issuer on such date and subject to acceleration upon a Change in Control as defined in the 2015 Plan.